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Haemophilia, which means love (“philia”) of blood (“haemo”),
is associated with prolonged and excessive bleeding. It is a
hereditary disorder of haemostasis that occurs in one in 5000
men (prevalence of 10 in 100 000 people) and is caused by a
deficiency of clotting factor VIII (in haemophilia A) or factor
IX (in haemophilia B) as a result of defects in the F8 and F9
genes. Basic knowledge of the inheritance and management of
haemophilia is essential for a broad group of healthcare workers,
because severe or even life threatening bleeding can be
prevented if the condition is adequately diagnosed and promptly
treated. Furthermore, in women carriers who have an affected
fetus, special precautions are needed to prevent perinatal
bleeding in both the mother and the newborn baby. This review
presents current recommendations for the diagnosis and
management of haemophilia, which are generally based on
observational studies and case series because few randomised
clinical trials have been published in this relatively rare disease.
What causes haemophilia?
When the body is injured, the haemostatic process is
immediately initiated to protect the body’s integrity and to
prevent further bleeding. Activation of platelets at the site of
injury is followed by sequential activation of clotting factors
and fibrin formation. Factor VIII and factor IX are essential for
enhancement of thrombin generation and propagation of fibrin
formation. Circulating factor VIII is bound to von Willebrand
factor (VWF) to protect it from proteolytic degradation.1 Both
factor VIII and factor IX are encoded by genes located on the
long arm of the X chromosome. When the F8 or F9 gene
sequence is disrupted, the synthesis of factor VIII or factor IX
is reduced or absent, or a less functionally active form is
produced (http://hadb.org.uk/).2 3
How can patients with haemophilia be
identified?
The severity of bleeding symptoms in patients with haemophilia
depends on the residual plasma concentration of the deficient
coagulation factor. Coagulation factor concentration is expressed
in international units (IU); 1 IU is defined as the concentration
of coagulation factor in 1 mL of normal pooled plasma. Healthy
people have a factor VIII or factor IX plasma concentration of
0.50-1.50 IU/mL. Factor VIII or factor IX concentrations can
also be expressed as percentages of normal pooled plasma
(defined as 100%), with normal levels between 50% and 150%.
Patients with haemophilia are classified into three severity
groups: severe, moderate, and mild.4 Patients with severe
haemophilia have no measurable factor VIII or factor IX (<0.01
IU/mL or <1%) andmay bleed spontaneously without preceding
trauma. In patients with moderate and mild haemophilia, the
plasma factor VIII or factor IX concentration is 0.02-0.05 IU/mL
(or 2-5%) or 0.06-0.40 IU/mL (or 6-40%), respectively.
Excessive bleeding usually occurs after minor trauma, dental
procedures, or surgery.
The diagnosis of haemophilia can be established shortly after
birth of an affected son when the mother is a known carrier.
When this is not the case, the diagnosis is established when
bleeding symptoms occur, either spontaneously or after mild
trauma. Characteristic bleeding symptoms are intracranial
bleeding in full term infants after delivery, painful swelling of
the joints caused by haemarthroses, unexplained bruising when
the baby starts to crawl or walk, postoperative bleeding,
extensive subcutaneous bleeding after venepuncture, andmuscle
bleeding—either spontaneously or after intramuscular
vaccination.
How is the diagnosis of haemophilia
established?
Haemorrhagicmanifestations that cannot be explained by trauma
and prolonged or excessive bleeding after surgical or dental
procedures require a thorough haemostatic laboratory evaluation,
including activated partial thromboplastin time and analysis of
factor VIII and factor IX. Patients with haemophilia usually
have a prolonged activated partial thromboplastin time, although
a normal result cannot rule out a mild form of haemophilia.
Before a definite diagnosis of mild haemophilia A is established,
a defect in the binding of factor VIII and VWF, which can also
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Summary points
In patients with major (head) trauma or major spontaneous bleeding, always give coagulation factor concentrates without delay, before
diagnostic imaging or other interventions
Prophylactic administration of factor VIII or factor IX concentrate is the standard of care for patients with severe haemophilia in countries
where this is economically feasible
Avoid drugs that affect haemostasis, such as platelet inhibitors and anticoagulants because they aggravate bleeding symptoms
A safety amulet that makes patients with haemophilia easily recognisable may be life saving and is recommended for all patients
Advise female relatives of patients with haemophilia to seek genetic counselling because they may be carriers
Female carriers may have reduced plasma concentrations of factor VIII or factor IX, similar to those seen in patients with mild haemophilia
and may also have bleeding symptoms
Sources and selection criteria
We searched Medline and the Cochrane Database of Systematic Reviews for “haemophilia” and “hemophilia”, and we consulted the TRIP
database for national guidelines on the management of haemophilia. Finally, we also used our personal reference libraries, giving preference
to the highest level of evidence available.
cause reduced concentrations of factor VIII, needs to be ruled
out. This defect characterises type 2N or “Normandy type” von
Willebrand disease, which can also affect female patients
because unlike haemophilia it is inherited in an autosomal
pattern. The diagnosis of type 2N von Willebrand disease can
be established by special binding assays or by molecular genetic
testing.5 Bleeding in patients with type 2N von Willebrand
disease is treated by administration of VWF concentrate.
Use of clotting factor concentrates to treat
haemorrhages
Bleeding in patients with haemophilia is treated by
administration of the deficient clotting factor. The first clotting
factor concentrates were derived from plasma and became
available around 1970. Recombinant factor VIII and factor IX
concentrates were developed in the 1990s. As stated in a recent
UK guideline, these are currently the preferred treatment for
children in the developed world, and for adult patients in some
countries, such as the United Kingdom and Sweden.6
The dose and duration of clotting factor administration depends
on the severity and type of bleeding. An important treatment
principle in case of major (head) trauma or bleeding is: factor
first. Coagulation factor concentrates should always be
administered without delay before performing diagnostic
imaging or other interventions. This strategy can be life saving
because clotting factors are a prerequisite for the immediate
arrest of haemorrhage in patients with haemophilia.
Unfortunately, this need is not always recognised, and
preventable morbidity or death does still occur.
When aiming for specific factor VIII or factor IX plasma
concentrations, the following rules of thumb apply: 1.0 IU/kg
body weight of factor VIII concentrate increases the plasma
concentration by about 0.02 IU/mL and 1.0 IU/kg body weight
of factor IX concentrate increases the plasma concentration by
about 0.01 IU/mL. In case of a life threatening bleed, aim for a
plasma concentration of 1.00 IU/mL for either factor. This can
be achieved by infusion of 50 IU/kg of factor VIII concentrate
or 100 IU/kg of factor IX concentrate. The short half lives of
these factors—six to 12 hours for factor VIII and about 24 hours
for factor IX—require repeated administration of clotting factor
concentrates to maintain plasma concentrations above the
haemostatic threshold of 0.40-0.50 IU/mL. For joint bleeds one
or two infusions are often enough, whereas intracranial bleeds
may need treatment for up to two weeks.
Are there alternative treatments to clotting
factor concentrates?
In patients with mild haemophilia A, minor bleeding may be
managed by infusion of desmopressin, which can be given
intravenously (0.3 µg/kg body weight) or intranasally (150 µg
in children or 300 µg in adults). A robust experimental study
showed that desmopressin increases factor VIII plasma
concentrations threefold to fivefold by inducing the release of
VWF.7 Because large differences are seen in the response to
this drug, it is important to measure the effect of a test dose of
desmopressin in each individual patient. The effect of the drug
decreases after consecutive administrations as stored VWF is
depleted. Desmopressin cannot be used in the treatment of
haemophilia B.
For mucocutaneous bleeding in haemophilia A and B
(supplementary) treatment with tranexamic acid is effective
(25-50 mg/kg/day; maximum dose of 4 g in three to four oral
or intravenous doses).
Whenever possible avoid drugs that impair haemostasis, such
as platelet inhibitors and anticoagulant drugs, because these will
aggravate bleeding symptoms.
Use of prophylaxis to prevent joint
damage
Repetitive joint bleeding may cause extensive damage to the
synovia by deposition of iron and subsequent chronic
inflammation. This causes pain, swelling, and instability of the
joint, predisposing it to further bleeding and ultimate
development of arthropathy: painful joint deformation with
limited function.
To prevent haemarthrosis, a recent UK guideline recommended
prophylactic administration of factor VIII or factor IX
concentrate two to three times a week as the standard of care
for patients with severe haemophilia A or B who live in
countries where this is economically feasible.8 Patients with
moderate or mild haemophilia are generally treated “on
demand”—only when bleeding occurs. A well conducted
randomised clinical trial in 65 boys with severe haemophilia A
recently established the benefits of prophylaxis. The relative
risk of joint damage detected by magnetic resonance imaging
at the age of 6 years with on demand treatment versus
prophylaxis was 6.1 (95% confidence interval 1.5 to 24.4).9 This
beneficial effect was confirmed in another randomised trial of
45 children.10 A well designed case-control study established
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that prophylaxis also protects against intracranial haemorrhage
(odds ratio 0.50, 0.32 to 0.77).11 Current guidelines on the use
of prophylaxis in patients with severe haemophilia A deal with
several aspects of care.8 12Most patients with severe haemophilia
infuse themselves with clotting factors at home. A national
survey found that this has greatly improved their health related
quality of life and reduced medical costs.13 14
In developing countries the availability of clotting factor
concentrates is limited, owing to restricted financial resources.
About 70% of the patients with haemophilia worldwide are
estimated not to receive adequate treatment. This is associated
with an enormous burden of musculoskeletal morbidity and
decreased life expectancy.15
How should surgery be managed?
To prevent haemorrhage during surgical or dental procedures
it is important to establish a perioperative management plan in
advance of the procedure. Factor VIII or factor IX concentrations
should be raised to 0.80-1.00 IU/mL immediately before surgery
and kept above 0.50 IU/mL for five to 14 days after the
operation, depending on the type and site of surgery. Guidelines
for perioperative care, based on a thorough review of the current
literature, are available.16
What are the complications of treatment
with clotting factor concentrates?
Themost challenging complication is the formation of inhibiting
antibodies (inhibitors) directed against active parts of the factor
VIII or factor IX protein, which decrease its coagulant
activity.17 18 Inhibitors usually occur in young children within
the first 50 days of treatment and increase the tendency to bleed.
Inhibitors often occur in haemophilia A (cumulative incidence
25% in patients with severe haemophilia A) but are rare in
haemophilia B. Bleeding episodes in patients with these
inhibitors can be prevented or treated with agents that bypass
the coagulant factors, such as recombinant factor VIIa
(Novoseven) or activated prothrombin complex (FEIBA). A
recent well conducted randomised crossover trial in 26 patients
with inhibitors showed that prophylactic treatment with activated
prothrombin complex reduced haemarthrosis by 61% compared
with on demand treatment.19 To eradicate the inhibitors, frequent
administration (twice a week to daily) of high doses of factor
VIII or factor IX is needed, a regimen called immune tolerance
induction, which may be continued for months or even years.20
Allergic reactions to clotting factor concentrates are extremely
rare because current concentrates are very pure. However, severe
anaphylactic reactions are possible after administration of factor
IX concentrates in patients with factor IX inhibitors.
In the 1980s, all clotting factor concentrates were derived from
plasma pooled from large numbers of blood donors. This
facilitated transmission of blood borne viruses such as hepatitis
B and C and HIV when untested blood from unscreened donors
was used, with devastating consequences. Currently, plasma
clotting factor concentrates are considered safe with regard to
transmission of these viruses because donors are tested
extensively before blood donation and viral inactivating
procedures are performed.
Carriers of haemophilia can have bleeding
symptoms too
Haemophilia is an X linked hereditary disease that affects men.
Women are carriers of the disease. However, female carriers
may also have reduced concentrations of coagulant factors owing
to inactivation of one X chromosome per somatic cell. A cross
sectional observational study of 223 female carriers found that
23% of these women had plasma factor VIII or factor IX
concentrations below 0.40 IU/mL—within themild haemophilia
range. These reduced concentrations of coagulant factors were
associated with bleeding symptoms.21
Plasma concentrations of factor VIII or factor IX should be
measured in all potential carriers, preferably at a young age
before surgical procedures take place. Carriers with factor
concentrations below 0.50 IU/mL should receive regular care
from a haemophilia treatment centre. Oral contraceptives and
antifibrinolytics (such as tranexamic acid) are effective in
reducing blood loss in women with menorrhagia.22Haemostasis
should be optimised before any invasive procedure, as it is for
patients with mild haemophilia.
A normal factor concentration does not rule out carrier status,
which can be excluded only by molecular genetic analysis.
How are pregnancy and deliverymanaged
in carriers of haemophilia?
All daughters of a patient with haemophilia are obligate carriers.
Daughters of a carrier or other female relatives of a person with
haemophilia have a 0-50% chance of being a carrier. A recent
UK guideline has based the following recommendations on a
thorough review of the literature. Carriers of haemophilia should
be identified by genetic counselling, which should be offered
from around the age of 16 years and should provide information,
education, and active counselling on the different reproductive
options—accepting the risk, undergoing prenatal diagnosis,
opting for preimplantation genetic diagnosis, adopting a child,
or remaining childless.23 Prenatal diagnosis by chorion villus
sampling at 11-14 weeks’ gestation is a widely used invasive
procedure that has a small but not negligible rate (0.5-1%) of
pregnancy loss.23 Preimplantation genetic diagnosis combines
assisted reproductive technology with molecular genetics and
cytogenetics to allow affected embryos to be identified before
implantation.24
The recent evidence based UK guideline recommends that
pregnancy and childbirth bemanaged in a haemophilia treatment
centre by a multidisciplinary team including a (paediatric)
haematologist, obstetrician, and anaesthesiologist.25 The sex of
the fetus can be identified by Y chromosome polymerase chain
reaction in maternal blood at around 10 weeks’ gestation or by
ultrasound scan at 18-20 weeks’ gestation.26Haemostasis should
be corrected during delivery in carriers with factor VIII or factor
IX plasma concentrations below 0.50 IU/mL. In the third
trimester of pregnancy, factor VIII values may rise temporarily,
but values drop quickly after delivery, placing the mother at
risk of postpartum haemorrhage. Thus, prophylactic
administration of clotting factor concentrates, desmopressin, or
antifibrinolytics should be considered in the postpartum period.
A systematic review found that desmopressin is effective in
reducing bleeding complications associated with pregnancy and
childbirth in selected cases.27However, at the time of childbirth,
desmopressin must be used with extreme caution because it can
cause severe hypotension, fluid retention, hyponatraemia, and
seizures in both mother and child.
Two observational cohort studies from the Netherlands and
Sweden showed that instrumental delivery (ventouse and
forceps) poses a significant risk (relative risk 17.8, 4.0 to 78.4
and 12.9, 5.4 to 32.6) for the respective studies in newborns
with haemophilia compared with spontaneous deliveries or
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caesarean sections.28 29 This was confirmed in a large European
cohort study.30Ventouse extraction and forceps are to be avoided
in newborns with suspected haemophilia. There is considerable
debate on the indication for elective caesarean section.25 The
option of elective caesarean section in an attempt to reduce the
risk of neonatal intracranial haemorrhage should be considered
on an individual basis, taking the fetal haemophilia status and
potential maternal morbidity into account.25Haemophilia carrier
status itself is not a contraindication to a vaginal delivery. A
caesarean section should be performed early if the vaginal
delivery does not proceed normally. There is no evidence for
the benefit of routine neonatal ultrasound screening or postnatal
prophylactic administration of clotting factors to reduce or
prevent intracranial haemorrhage in the newborn.
Future of haemophilia treatment
Several new developments in haemophilia care have emerged
in the past few years. Long acting factor VIII and factor IX
concentrates that enable less frequent prophylactic dosing are
currently being tested in clinical trials.31 These proteins have
been engineered by site directed glycopegylation or the fusion
of albumin or IgG to the clotting factors. Several research groups
have made great progress with gene therapy in the past few
years.32 Recently, six patients with haemophilia B were infused
with a single dose of adenovirus associated virus vector
expressing a human factor IX transgene. They showed sustained
low level expression of human factor IX for six to 16 months
without side effects and minor immune responses against the
vector.33 Four of the six patients could discontinue their
prophylaxis without the occurrence of spontaneous bleeding.
Long term efficacy data are crucial for the future of this
approach.
Conclusion
Haemophilia can be treated safely and effectively by infusion
of clotting factor concentrates that are currently available. Joint
impairment may be prevented by regular administration of such
concentrates. In emergency trauma situations immediate
administration of clotting factor concentrates is necessary. All
potential carriers should be identified to optimise genetic
counselling and haemostasis at the time of delivery. This may
prevent excessive bleeding in the mother and any newborns
with haemophilia. Because haemophilia is a rare disease that
needs a multidisciplinary approach, patients should be cared for
in comprehensive care haemophilia treatment centres.34
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Ongoing and future research questions
Will gene therapy be the ultimate answer to haemophilia?
Will oral treatment of haemophilia ever be possible?
How can we prevent the development of inhibitors?
How can joint bleeding best be prevented in patients with inhibitors?
How can the eradication of inhibitors be improved?
Can we make treatment available for all patients with haemophilia around the globe?
Additional educational resources
Resources for patients
World Federation of Hemophilia (www.wfh.org)—A global network of healthcare providers, national haemophilia associations, people
with haemophilia, and their families
Centers for Disease Control and Prevention (www.cdc.gov/ncbddd/hemophilia/people.html)—Information for patients and their families
Resources for healthcare professionals
International Society on Thrombosis and Haemostasis (www.isth.org)—Society with more than 3000 members (doctors and researchers)
from more than 80 countries
American Society of Hematology (www.hematology.org/)—The world’s largest professional society concerned with the causes and
treatment of blood disorders
European Association of Haemophilia and Allied Disorders (www.eahad.org)—Amultidisciplinary association of healthcare professionals
who provide care for patients with haemophilia and other bleeding disorders
Haemophilia A Mutation, Structure, Test and Resource Site (http://hadb.org.uk) and CDC Hemophilia A Mutation Project (www.cdc.gov/
ncbddd/hemophilia/champs.html)—Databases with mutations of factor VIII associated with haemophilia
Haemophilia B Mutation Database (www.kcl.ac.uk/ip/petergreen/haemBdatabase.html)—Database with mutations of factor IX associated
with haemophilia
A parent’s perspective
Daniel and Sep are 7 year old twin brothers with haemophilia A. They have a 14 year old brother and two sisters, aged 17 and 19 years,
who are healthy. I discovered that I was a haemophilia carrier when the twins started to have bleeding symptoms at 6 months of age. Daniel
started to have strange big bruises, first in his upper arm—did we grab him too firmly? We were summoned to the healthy baby clinic and
directly referred to the general practitioner, who concluded that child abuse must have occurred. After that, my husband hardly dared to
touch the babies. At some time later Daniel’s cheek became very hard. We immediately visited the emergency department of the local
hospital, where his blood was tested. The next day we were referred to the haemophilia treatment centre in Amsterdam. The centre confirmed
that Daniel had haemophilia and tested Sep, who did not yet have any symptoms, as well. Both boys had severe haemophilia A. At the age
of 14 months they were started on prophylaxis. We knew nothing about the disease at the time of diagnosis, but the team at the haemophilia
treatment centre has shown us the way, coached us, and guided us.
Tips for non-specialists
Unexplained excessive bleeding at any age, especially intracranial haemorrhage in term baby boys, justifies a haemostatic investigation,
including coagulation screening tests and determination of factor VIII and factor IX plasma concentrations
No surgical or dental procedure should be performed in patients with haemophilia without consultation with the patient’s haemophilia
treatment centre. An authorised treatment regimen will ensure adequate haemostasis during the intervention
Desmopressin is useful in the treatment of mild haemophilia A, but test the individual patient’s response to the drug before administration
to assess whether it is sufficient to ensure haemostasis during haemorrhage and procedures
Major trauma and head trauma in patients with haemophilia can be life threatening and require immediate administration of clotting
factor concentrates, before performing diagnostic imaging and other interventions
The development and increased availability of safe clotting factor concentrates as well as the enrolment of patients in comprehensive
care programmes has greatly improved the clinical outcome and quality of life of these patients
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